IRIS
CICCARELLI, LEONARDINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.664
AS - Asia 2.286
EU - Europa 1.859
SA - Sud America 206
AF - Africa 19
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 4
Totale 7.042
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.614
CN - Cina 1.475
IE - Irlanda 516
SG - Singapore 438
UA - Ucraina 368
DE - Germania 261
FI - Finlandia 244
HK - Hong Kong 205
RU - Federazione Russa 182
BR - Brasile 174
SE - Svezia 102
IT - Italia 71
GB - Regno Unito 49
VN - Vietnam 48
CA - Canada 36
IN - India 30
FR - Francia 18
BD - Bangladesh 13
IQ - Iraq 13
NL - Olanda 11
AR - Argentina 10
MX - Messico 10
PL - Polonia 10
JO - Giordania 9
TR - Turchia 9
ZA - Sudafrica 9
EC - Ecuador 7
LT - Lituania 7
IR - Iran 6
JP - Giappone 6
VE - Venezuela 6
CL - Cile 4
EU - Europa 4
PK - Pakistan 4
UZ - Uzbekistan 4
AE - Emirati Arabi Uniti 3
BE - Belgio 3
ES - Italia 3
MA - Marocco 3
NP - Nepal 3
NZ - Nuova Zelanda 3
SA - Arabia Saudita 3
AL - Albania 2
AT - Austria 2
BB - Barbados 2
BO - Bolivia 2
ID - Indonesia 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LU - Lussemburgo 2
PY - Paraguay 2
AD - Andorra 1
AO - Angola 1
AU - Australia 1
AZ - Azerbaigian 1
BN - Brunei Darussalam 1
CI - Costa d'Avorio 1
CO - Colombia 1
CY - Cipro 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
EG - Egitto 1
GE - Georgia 1
GR - Grecia 1
HR - Croazia 1
IL - Israele 1
KE - Kenya 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
MD - Moldavia 1
OM - Oman 1
PH - Filippine 1
PT - Portogallo 1
RO - Romania 1
SI - Slovenia 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
UG - Uganda 1
Totale 7.042
Salva come PNG Salva come JPEG
Città #
Dublin 516
Jacksonville 480
Chandler 396
Nanjing 350
Beijing 226
Dallas 210
Hong Kong 205
Ashburn 170
Singapore 163
Nanchang 156
Boardman 149
Shenyang 121
Princeton 107
Jiaxing 103
Wilmington 103
Changsha 100
Lawrence 95
Hebei 92
Medford 81
Tianjin 66
Los Angeles 58
Hangzhou 52
Munich 39
Buffalo 37
Helsinki 36
Redondo Beach 35
New York 25
Shanghai 25
Toronto 25
Moscow 24
Seattle 24
Norwalk 22
Turku 18
São Paulo 17
Ho Chi Minh City 14
Woodbridge 13
Fairfield 12
San Francisco 12
Des Moines 11
Jinan 11
Pune 11
Ann Arbor 10
Atlanta 10
Hanoi 10
Milan 10
Amman 9
Frankfurt am Main 9
Johannesburg 8
Kunming 8
Santa Clara 8
Dearborn 7
Orem 7
Warsaw 7
Belo Horizonte 6
Eindhoven 6
Lanzhou 6
London 6
Poplar 6
Verona 6
Baghdad 5
Brooklyn 5
Guangzhou 5
Ningbo 5
Quito 5
Rome 5
Taizhou 5
Tokyo 5
Washington 5
Chennai 4
Halifax 4
Montreal 4
Orange 4
Porto Alegre 4
Rio de Janeiro 4
Stockholm 4
Tehran 4
Zhengzhou 4
Boston 3
Brussels 3
Campinas 3
Curitiba 3
Dubai 3
Fuzhou 3
Manchester 3
Recife 3
Tashkent 3
Wroclaw 3
Wuhan 3
Ankara 2
Annapolis 2
Bishkek 2
Biên Hòa 2
Brasília 2
Bridgetown 2
Bắc Giang 2
Caracas 2
Carney 2
Charleston 2
Charlotte 2
Chicago 2
Totale 4.687
Salva come PNG Salva come JPEG
Nome #
Comparison between diet, orlistat and fluvastatin in obese patients with mild hypertension and hypercholesterolemia 112
Confronto tra nateglinide più metformina rispetto a glibenclamide più metformina sul metabolismo glucidico nei pazienti diabetici di tipo 2: studio ad 1 anno 110
Confronto tra dieta, orlistat e fluvastatina in soggetti obesi, con ipertensione arteriosa lieve e ipercolesterolemia 109
Atorvastatin-amlodipine combination and fibrinolytic balance in hypertensive hypercholesterolemic insulin-resistent patients 107
Comparison between orlistat and sibutramine in obese patients with mild hypertension 106
Confronto tra pioglitazone e rosiglitazone sul metabolismo glucidico e lipidico nei soggetti diabetici di tipo 2 in terapia con metformina 106
Azione della moxonidina sul metabolismo glucidico e lipidico negli ipertesi con sindrome metabolica 105
Association between low-molecular weight apolipoprotein(a) isoforms and obesity in Italian women 102
Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial 101
Comparison between exenatide and glimepiride on metabolic control and on insulin resistance in type 2 diabetic patients with metformin therapy 99
Actions of glimepiride plus metformin compared to rosiglitazone plus metformin on glucose metabolism, fibrinolytic, and coagulation measurements in Type 2 diabetic patients. 99
Effetti metabolici di telmisartan e irbesartan nei pazienti diabetici di tipo 2 con sindrome metabolica trattati con rosiglitazone 96
Effetti di pioglitazone e rosiglitazone nei pazienti con diabete di tipo 2 e sindrome metabolica trattati con metformina 95
Comparison between fosinopril and eprosartan on lipid profile and Lp(a) in normotensive, type 2 diabetic subjects, with microalbuminuria 93
Comparison between glimepiride plus pioglitazone vs. glimepiride plus rosiglitazone on glucose metabolism and on lipid, lipoprotein and apolipoprotein fractions in type 2 diabetic patients 92
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients 91
Azione della moxonidina sul metabolismo glucidico e lipidico negli ipertesi con sindrome metabolica 91
Metalloproteasi-2, metalloproteasi-9 ed inibitore tissutale delle metalloproteasi-1 in pazienti ipertesi 90
Effects of rosiglitazone alone and in association with simvastatin on lipid and lipoprotein parameters in patients with metabolic syndrome 89
Effetti metabolici di telmisartan e irbesartan nei apzienti diabetici di tipo 2 con sindrome metabolica trattati con rosiglitazone 86
The efficacy and safety of pioglitazone or rosiglitazone added onto metformin in type 2 diabetes patients with metabolic syndrome 86
Le metalloprotesi -2 e -9 e i loro inibitori tissutali -1 e -2 nei soggetti sani e nei soggetti con diabete di tipo 2 86
Changes during glimepiride plus rosiglitazone vs glibenclamide plus rosiglitazone treatment on glucose metabolism and lipoprotein (a) in Type 2 diabetic patients. 85
Effetti dell'associazione tra pioglitazone e sibutramina sul metabolismo glucidico e lipidico nei soggetti obesi diabetici di tipo 2 85
Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic insulin-resistant patients 85
Comparison between repaglinide plus metformin vs glimepiride plus metformin on glucose metabolism, fibrinolytic, and coagulation measurements in Type 2 diabetic patients: a 1 year 83
Doxazosin improves blood pressure and metabolic parameters in impaired glucose tolerance patients in therapy with acarbose 83
MMP-2, -9 and TIMP-1 in patients with hypertension before and after doxazosin therapy 82
The efficacy and safety of pioglitazone or rosiglitazone added onto metformin on diabetic dyslipidemia 81
La doxazosina migliora i parametri pressori e l'assetto metabolico nei soggetti intolleranti al glucosio in terapia con acarbose 81
Efficacia e sicurezza di pioglitazone o rosiglitazone in combinazione con metformina in pazienti con diabete di tipo 2 e sindrome metabolica 79
Efficacy of fluvastatin together with fenofibrate in hypercholesterolemic type 2 diabetic subjects compared to monotherapy. 78
Fosinopril vs eprosartan in normotensive, Type 2 diabetic patients, with microalbuminuria 77
Matrix metalloproteinases and tissue inhibitor metalloproteinases in hypertensive patients 76
High Lp(a) levels and atherogenic isoforms in patients with acute coronary sindrome 75
Efficacia di fluvastatina e fenofibrato in prevenzione secondaria rispetto alla monoterapia: studio ad 1 anno in pazienti diabetici di tipo 2, ipercolesterolemici 75
La terapia con rosiglitazone migliora i parametri di insulino-resisitenza nei pazienti diabetici in sovrappeso ed obesi intolleranti alla metformina 75
The efficacy and safety of pioglitazone or rosiglitazone added onto metformin on diabetic dyslipidemia 74
Matrix metalloproteinase 2 and 9 values in various groups with or without diabetes 74
Comparison between Glimepiride Plus Rosiglitazone on Glucose Metabolism and on Lipid, Lipoprotein and Apolipoprotein Parameters in Type 2 Diabetic Patients 74
Comparison between glimepiride plus metformin vs rosiglitazone plus metformin on glucose metabolism and on blood pressure in Type 2 diabetic patients 74
Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients 73
Efficacia e sicurezza del pioglitazone o rosiglitazone in combinazione con metformina su pazienti diabetici dislipidemici 73
Matrix metalloproteinase-2,-9 and tissue inhibitor metalloproteinase-1,-2 in healthy and type 2 diabetic subjects 73
Matrix metalloproteinases and tissue inhibitor metalloproteinases in hypertensive patients before and after antihypertensive therapy 72
Effects of exenatide compared to glibenclamide on glycemic control and on insulin resistance in type 2 diabetic patients with metformin therapy 71
Moxonidine action on glucose and lipid metabolism in hypertensive patients with metabolic syndrome 71
Comparison between repaglinide plus metformin vs glimepiride plus metformin on glucose metabolism and lipoprotein (a) in type 2 diabetic patients: A 1-year study 71
Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin 70
Glycemic and extraglycemic effects of glimepiride plus pioglitazone vs glimepiride plus rosiglitazone therapy in Type 2 diabetic patients 70
Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone: a double-blind, randomised clinical trial 70
Matrix metalloproteinase-2, -9 and tissue inhibitor metalloproteinase-1, -2 in healthy and type 2 diabetic subjects 70
Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone 70
Pioglitazone or rosiglitazone added onto metformin in type 2 diabetes with metabolic syndrome: effects on conventional and non-conventional cardiovascular risk factors 70
La doxazosina migliora i parametri pressori e l'assetto metabolico nei soggetti intolleranti al glucosio in terapia con acarbose 70
Le metalloproteasi-2, -9 in differenti gruppi con e senza diabete 69
Matrix metalloproteinase 2 and 9 evaluation in different patient groups with or without diabetes 69
Matrix metalloproteinase 2 and 9 levels in diabetic and nondiabetic patients during and after acute coronary syndrome 68
Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin 67
Effects of telmisartan compared to nifedipine in hypertensive, type 2 diabetic patients on glucose metabolism and lipid profile: a 1-year study 67
Effetti metabolici di telmisartan e irbesartan nei pazienti diabetici di tipo 2 con sindrome metabolica trattati con rosiglitazone 67
La doxazosina migliora i parametri pressori e l'assetto metabolico nei soggetti intolleranti al glucosio in terapia con acarbose 67
Efficacy of fluvastatin together with fenofibrate in secondary prevention compared to monotherapy in hypercholesterolemic, type 2 diabetic subjects: A 1-year study 66
The efficacy and safety of pioglitazone or rosiglitazone added onto metformin in type 2 diabetes patients with metabolic syndrome 66
Matrix metalloproteinase 2 and 9 values in various groups with or without diabetes 66
Valutazione endocrino-metabolica di una popolazione di pazienti obesi e confronto con soggetti normopeso 66
Valutazione delle metalloproteasi 2 e 9 in pazienti con o senza diabete durante sindrome coronarica acuta e dopo evento acuto 65
Matrix metalloproteinase-2,-9 and tissue inhibitor metalloproteinase-1,-2 in patients with acute coronary syndrome with or without diabetes during and after acute event 65
Matrix metalloproteinase-2, -9 and tissue inhibitor Metalloproteinase-1 in patients with hypertension 64
Matrix metalloproteinase-2, -9, and tissue inhibitor metalloproteinase-1 in patients with hypertension before and after doxazosin therapy 64
Effetti di exenatide in combinazione con metformina sulla funzione beta-cellulare in pazienti affetti da diabete mellito di tipo 2 63
Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: A randomized placebo-controlled trial 63
Stress ossidativo e rischio vascolare. Quale ruolo per gli antiossidanti? 63
Metabolic and insulin resistance-related indices during pioglitazone and vildagliptin association versus glimepiride and vildagliptin association in type 2 diabetic patients 63
Pioglitazone and sitagliptin compared to pioglitazone and metfomin therapy on glycaemic control and on insulin resistance in type 2 diabetic patients 62
Il sistema di monitoraggio continuo della glicemia nei soggetti sani: risultato di uno studio pilota 62
The efficacy and safety of pioglitazone or rosiglitazone added onto metformin on diabetic dyslipidemia 62
Prevalenza di elevati livelli di Lp(a) e di isoforme aterogene in un gruppo di pazienti del Nord Italia con sindrome coronarica acuta 61
Terapia con telmisartan e irbesartan nei pazienti con diabete di tipo 2 trattati con rosiglitazone: effetti sull'insulino-resistenza, leptina e TNF-alfa 61
La sibutramina non modifica i parametri emodinamici bnegli obesi, diabetici di tipo 2 61
Pioglitazone or rosiglitazone added onto metformin in type 2 diabetes patients with metabolic syndrome: effects on conventional and non-conventional cardiovascular risk factors 61
Fenofibrate and fluvastatin compared to monotherapy in hypercholesterolemic diabetic patients with coronary heart disease: a 1 year study 61
Pioglitazone o rosiglitazone in associazione con metformina nei pazienti con diabete mellito di tipo 2 e sindrome metabolica: effetto sui fattori di rischio cardiovascolare convenzionali e non convenzionali 60
Glycemic control and cardiovascular risk profile in patients with type 2 diabetes treated with repaglinide or metformin 58
Pioglitazone or rosiglitazone added onto metformin in type 2 diabetes patients with metabolic syndrome: effects on markers of cardiovascular disease 58
Le metalloproteasi-2, -9 nei pazienti diabetici con sindrome coronarica prima e dopo l'evento acuto 57
Lipid and lipoprotein effects of rosiglitazone alone and in association with simvastatin in patients with metabolic syndrome 55
Valutazione delle metalloproteasi 2 e 9 in differenti gruppi di pazienti con o senza diabete 55
The improvement of Insulin-Resistance with Rosiglitazone Plus Metformin Compared to Glimepiride Plus Metformin Lowers Blood Pressure Values in Type 2 Diabetic Patients 54
Effects of Telmisartan Compared to Nifedipine in Hypertensive, Type 2 Diabetic Patients on Glucose Metabolism and Lipid Profile: A 1-Year Study 53
Effetti dell'associazione tra pioglitazone e sibutramina sul metabolsimo glucidico e lipidico nei soggettiobesi diabetici di tipo 2 51
Effetti metabolici di telmisartan e irbesartan nei pazienti diabetici di tipo 2 con sindrome metabolica trattati con rosiglitazone 50
Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes 45
Effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin 43
Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone 43
Totale 7.062
Salva come PNG Salva come JPEG
Categoria #
all - tutte 29.621
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.621
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021423 0 0 0 0 0 87 0 111 15 98 95 17
2021/2022350 0 0 18 1 1 0 4 23 12 2 69 220
2022/20231.329 121 105 2 67 129 139 0 86 602 7 47 24
2023/2024410 30 103 19 32 32 103 5 43 3 12 12 16
2024/20251.068 8 107 46 37 10 31 61 77 262 6 115 308
2025/20261.249 261 175 261 217 267 68 0 0 0 0 0 0
Totale 7.062